Home›Icosapent Ethyl

Icosapent Ethyl

Also known as: Icosapent Ethyl

Route: Oral

2 interactions on record

Icosapent Ethyl has 2 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Acidifying Agents, Oral Anticoagulants. Patients taking Icosapent Ethyl should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 2
Moderate: 2

Moderate (2)

Icosapent Ethyl + Acidifying Agents— Omega-3 fatty acids may prolong bleeding time. Monitor patients for bleeding when icosapent ethyl is used concomitantly …
Icosapent Ethyl + Oral Anticoagulants— Omega-3 fatty acids may prolong bleeding time. Monitor patients for bleeding when icosapent ethyl is used concomitantly …

Icosapent Ethyl + Acidifying Agents🟡Moderate

Omega-3 fatty acids may prolong bleeding time. Monitor patients for bleeding when icosapent ethyl is used concomitantly with antiplatelet agents.

Icosapent Ethyl + Oral Anticoagulants🟡Moderate

Omega-3 fatty acids may prolong bleeding time. Monitor patients for bleeding when icosapent ethyl is used concomitantly with anticoagulants.

Contraindications

4 CONTRAINDICATIONS Icosapent ethyl capsules are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to icosapent ethyl or any of its components. Icosapent ethyl capsules are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to icosapent ethyl or any of its components. (4)

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary The available data from published case reports and the pharmacovigilance database on the use of icosapent ethyl in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies in pregnant rats, non-dose-related imbalances for some minor developmental findings were observed with oral administration of icosapent ethyl during organogenesis at exposures that were equivalent to the clinical exposure at the human dose of 4 g/day, based on body surface area comparisons. In a study in pregnant rabbits orally administered icosapent ethyl during organogenesis, there were no clinically relevant adverse developmental effects at exposures that were 5 times the clinical exposure, based on body surface area comparisons ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In pregnant rats given oral gavage doses of 0.3, 1 and 2 g/kg/day icosapent ethyl from gestation through organogenesis all drug treated groups had non-dose-related imbalances in visceral and skeletal findings, including 13 th reduced ribs, additional liver lobes, testes medially displaced and/or not descended, at human systemic exposures following a maximum oral dose of 4 g/day based on body surface comparisons. In a multigenerational developmental study in pregnant rats given doses of 0.3, 1, 3 g/kg/day icosapent ethyl by oral gavage from gestation day 7-17, icosapent ethyl did not affect viability in fetuses (F 1 or F 2 ). Non-dose-related imbalances in findings of absent optic nerves and unilateral testes atrophy at human exposures

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.